Mechanisms of Peripheral and Central Sensitization in Osteoarthritis Pain

Yoshihisa Ohashi, Kentaro Uchida, Kensuke Fukushima, Gen Inoue, Masashi Takaso

Department of Orthopaedic Surgery, Kitasato University School of Medicine, Sagamihara, JPN

Corresponding author: Kentaro Uchida, kuchida@med.kitasato-u.ac.jp

Introduction And Background

Osteoarthritis (OA), the most common form of arthritis, is a painful chronic disease of the synovial joints. Chronic pain and its related symptoms in OA reduce both the quality and quantity of life [1,2]. Understanding OA pain is hindered by the fact that it can be intense or chronic, regardless of the degree of structural change. Indeed, several studies report that the association between radiographic structural changes and pain levels in OA is poor [3,4]. OA pain is subjective, involving both peripheral and central neural mechanisms, which are modulated not only by a wide range of neurochemical factors but additionally by environmental, psychological, and genetic factors [5-7]. Nevertheless, the mechanisms of OA pain are not well understood.

Pain sensitization is considered a key process in chronic pain conditions that are characterized by exaggerated responses to innocuous or only mildly noxious stimuli (hyperalgesia and allodynia) [8]. Two types of sensitization (peripheral sensitization [PS] and central sensitization [CS]) have been reported to affect chronicity and treatment resistance in OA pain [4,5,8-10]. PS is described as the hyperexcitability of peripheral nociceptors and is considered largely due to the effects of neurotrophins and pro-inflammatory molecules in promoting nociceptor depolarization [11,12]. CS by comparison, results from a continuous nociceptive input that occurs as hyperexcitability of wide dynamic range neurons in the dorsal horn (DH) [13]. More understanding of the pathophysiology of pain sensitization in OA may aid in the development of therapies that are better targeted at the direct mechanisms of pain.

Recent evidence suggests that pro-inflammatory cytokines, nerve growth factor (NGF), and serotonin are therapeutic targets for OA pain with PS and CS. This review aims to describe in detail the role of these factors in the mechanisms of pain sensitization, from PS to CS in OA.

Review

Peripheral sensitization in OA

Joint nociceptors are normally inactive but become active during arthritis due to cartilage damage or synovitis. These act to intensify joint pain [14]. In affected synovial tissues, the nociceptive system enters a state of hyperexcitability and can be activated by what are otherwise normal or usually innocuous or mild irritations [15]. Nociceptors in intra-articular tissues are known to be sensitized in electro-physiological studies in OA models in rats and guinea pigs [16,17]. Increased afferent nerve firing rate was observed in a monosodium iodoacetate (MIA)-induced OA model in rats [16]. Afferent nerve firing rate increased with aging in a guinea pig model of spontaneous OA [17]. Also, the mechanical threshold required to activate the afferent nerve fibers was significantly higher in aged guinea pigs compared to younger animals [17].
Inflammation-associated molecules, such as prostaglandins, bradykinin, tumor necrosis factor (TNF-α), interleukin (IL)-1β, IL-6, damage-associated molecular patterns (DAMPs) are thought to ligate to sensory nerve fibers via transient receptor potential (TRP) channels and sodium channels. This translates into a lower excitation threshold on high-threshold neurons, making joint nociceptors more likely to fire in response to painful stimuli, both noxious and non-noxious [18]. The signals then course via ascending pathways to high central nervous system (CNS) centers and are there interpreted as pain and assigned affective qualities [19]. An overview of the signaling pathways of PS in OA is indicated in Figure 1.

Central sensitization in OA

CS is defined as the elevated responsiveness of nociceptive neurons in the CNS to normal or subthreshold afferent inputs as a result of CNS plasticity [20]. An increase in spontaneous neuronal activity causes pain hypersensitivity by lowering activation thresholds and expanding the receptive field [9]. Pain hypersensitivity includes both hyperalgesia - an increased sensitivity to noxious stimuli - and allodynia - pain as a response to normally innocuous stimuli [21-23]. The mechanism of CS includes excessive nociceptive ascending (sensory) signaling and insufficient inhibitory descending signaling. This facilitation is maintained by peripheral nociceptive input arising from the OA joint itself [24]. DH of the spinal cord is where ascending pathways arise, where they synapse with interneurons or projection neurons that have synapsed with primary afferents. A pain signal is transmitted through these ascending pathways to the hypothalamus, thalamus, brainstem, amygdala, and prefrontal cortex [25]. An overview of the signaling pathways of CS in OA is indicated in Figure 1.

Molecules involved in PS and CS in OA

Pro-inflammatory Cytokines

TNF-α, IL-1β, and IL-6 are potent pro-inflammatory cytokines exerting pleiotropic effects on various cell types and play a critical role in the pathogenesis of chronic inflammatory diseases, such as OA and rheumatoid arthritis (RA). These molecules are released into the joint, and synovial inflammation is associated with pain in OA [26,27]. These cytokines facilitate the firing of joint nociceptors, leading to nociception and the initiation of OA pain [12,28-30]. In a study of rat models, intraarticular TNF-α injection resulted in persistent sensitization of nociceptive Aδ- and C-fibers, which lead to hyperalgesia and mechanical allodynia [12]. It has been suggested that IL-1β and IL-6 also activate or sensitize nociceptors [29,30]. Furthermore, in animal models of chronic inflammation, primary afferents in the DRG and post-nodal sympathetic fibers were reported to exhibit a neuropathy-like phenotype, with increased sprouting to the affected area and to the DRG itself [31]. Lee et al. revealed that elevated serum IL-6 levels are associated with low-pressure pain thresholds (PPTs) taken at sites remote to the affected joint and high suprathreshold heat pain ratings [32]. Leung et al. reported that concentrations of TNF-α, IL-6, and IL-8 are associated with
pain on movement, with only TNF-α being involved in the exacerbation of the pain at rest, which is characteristic of sensitized pain in the synovial fluid of knee OA (KOA) [33]. Further, it is known that these pro-inflammatory cytokines are primarily expressed by synovial monocytes and macrophages in OA joints [34-36]. Further, CD14-positive macrophages regulate NGF via pro-inflammatory cytokine production in the synovial membrane of KOA [34-36]. Synovial CD163 mRNA expression is positively correlated with pain at rest, while CD14+CD14 low macrophages expressing TNF-α might be a major contributor to hip OA (HOA) pain [34]. Considering the evidence, elevated synovial fluid and serum levels of pro-inflammatory cytokines in OA patients might directly trigger PS and contribute to CS.

Neurotransmitter Modulation

Serotonin

In order to modulate spinal nociceptive processing and modulate the descending pain responses, monoaminergic signaling is involved in the process, which originates from the midbrain, the medullary structures, and the subnucleus reticularis dorsalis [59]. Serotonin modulatory effects on pain are complex and dependent on various receptor subtypes being activated. It appears that alterations in serotonergic activity have led to a greater degree of CS. There are several models of persistent neuropathic pain, including spinal sensitization mediated by NGF [43]. NGF directly enhances acid-sensing ion channel 3 encoding genes in DRG neurons [47]. This triggers the sensitization of the nociceptor, resulting in a condition of PS. NGF may contribute indirectly to CS through its downstream influence on transcription. The NGF/TrkA complex is transported retrogradely to neuronal cell bodies in the DRG. The NGF/TrkA signal in turn drives the synthesis of pronociceptive components (brain-derived neurotrophic factor [BDNF], calcitonin gene-related peptide [CGRP], and substance P [SP]) [48-51]. BDNF activates spinal microglia and contributes to the induction and maintenance of the CS [52]. SP and CGRP are released from the peripheral endings of sensory neurons, which contribute to the development of neurogenic inflammation, while SP and CGRP are released from the central terminal of sensory neurons, which contribute to enhanced nociception and the buildup of CS [50]. Neuronal sensitization mediated by NGF/TrkA increases nociceptive signaling through the DH and supraspinal structures [42]. The overall effect is the condition of CS.

The release of NGF during cartilage degradation, bone remodeling, and synovial inflammation appears to play a pivotal role in the mechanical hyperalgesia that occurs in OA patients with pain symptoms. Results in models are illustrative: in one rat model, systemic administration of NGF caused mechanical and thermal hyperalgesia [33]. While in rat models of OA, intra-articular injection of NGF produced a decrease in the hind paw mechanical withdrawal threshold in one [54] and contributed to spinal nociceptive sensitization in another [55]. Our previous study described a positive correlation between expression levels of NGF mRNA in the synovial membrane and scores for the central sensitization inventory (CSI) and pain in patients with HOA [41]. These findings support previous evidence that monoclonal antibodies against NGF reduce pain symptoms from OA [56-58]. However, evidence for a direct association between PS and CS in human OA and NGF levels in intra-articular tissues such as synovial membrane, synovial fluids, cartilage, etc. is lacking, and further study is required.

TrkA signaling

Serotonin modulatory effects on pain are complex and dependent on various receptor subtypes being activated. It appears that alterations in serotonergic activity have led to a greater degree of CS. There are several models of persistent neuropathic pain, including spinal sensitization mediated by NGF [43]. NGF directly enhances acid-sensing ion channel 3 encoding genes in DRG neurons [47]. This triggers the sensitization of the nociceptor, resulting in a condition of PS. NGF may contribute indirectly to CS through its downstream influence on transcription. The NGF/TrkA complex is transported retrogradely to neuronal cell bodies in the DRG. The NGF/TrkA signal in turn drives the synthesis of pronociceptive components (brain-derived neurotrophic factor [BDNF], calcitonin gene-related peptide [CGRP], and substance P [SP]) [48-51]. BDNF activates spinal microglia and contributes to the induction and maintenance of the CS [52]. SP and CGRP are released from the peripheral endings of sensory neurons, which contribute to the development of neurogenic inflammation, while SP and CGRP are released from the central terminal of sensory neurons, which contribute to enhanced nociception and the buildup of CS [50]. Neuronal sensitization mediated by NGF/TrkA increases nociceptive signaling through the DH and supraspinal structures [42]. The overall effect is the condition of CS.

The release of NGF during cartilage degradation, bone remodeling, and synovial inflammation appears to play a pivotal role in the mechanical hyperalgesia that occurs in OA patients with pain symptoms. Results in models are illustrative: in one rat model, systemic administration of NGF caused mechanical and thermal hyperalgesia [33]. While in rat models of OA, intra-articular injection of NGF produced a decrease in the hind paw mechanical withdrawal threshold in one [54] and contributed to spinal nociceptive sensitization in another [55]. Our previous study described a positive correlation between expression levels of NGF mRNA in the synovial membrane and scores for the central sensitization inventory (CSI) and pain in patients with HOA [41]. These findings support previous evidence that monoclonal antibodies against NGF reduce pain symptoms from OA [56-58]. However, evidence for a direct association between PS and CS in human OA and NGF levels in intra-articular tissues such as synovial membrane, synovial fluids, cartilage, etc. is lacking, and further study is required.

Nerve Growth Factor

The pronociceptive functions necessarily involved in the pathogenesis of pain include PS and CS, and enhanced local neuronal sprouting at sites of inflammation, within the dorsal root ganglion (DRG), and possibly also within the DH [25]. NGF is associated with these functions. NGF is the founding member of the neurotrophin family of growth factors, which are responsible for the survival, growth, and developmental plasticity of neurons in the peripheral and CNS in vertebrates [37,38]. NGF is produced by chondrocytes, synovial macrophages, and fibroblasts in the osteoarthritic joint [35,39,40]. NGF production was stimulated by transforming growth factor (TGF)-β in osteoarthritic chondrocytes [39]. Synovial fibroblast had higher NGF production ability compared to macrophages following TNF-α stimulation [35,40]. CD14high positive cells had higher NGF expression compared to CD14low cells in HOA [41]. It binds tropomyosin-related kinase A (TrkA), which is expressed in a range of sensory and sympathetic fibers and regulates their survival [42]. TrkA-positive cells account for about 40% of neurons in the DRG. They include thin myelinated Aδ fibers and peptidergic unmyelinated C fibers, both of which innervate multiple tissues [42,43]. The binding of NGF to TrkA on the peripheral terminals of nociceptors and the surface of immune cells may directly play a role in acute PS [42]. NGF/TrkA complex leads to signaling that upregulates the local expression and activation of pronociceptive channels/receptors (Na/Ca/K channels, bradykinin receptors, cation channels, and acid-sensing ion channels) [44-47]. Bradykinin B2 receptor expression was elevated by NGF in mouse DRG culture [44]. The calcium current density increased in cultured embryonic basal forebrain neurons following NGF treatment [48]. NGF directly enhances acid-sensing ion channel 3 encoding genes in DRG neurons [47]. This triggers the sensitization of the nociceptor, resulting in a condition of PS. NGF may contribute indirectly to CS through its downstream influence on transcription. The NGF/TrkA complex is transported retrogradely to neuronal cell bodies in the DRG. The NGF/TrkA signal in turn drives the synthesis of pronociceptive components (brain-derived neurotrophic factor [BDNF], calcitonin gene-related peptide [CGRP], and substance P [SP]) [48-51]. BDNF activates spinal microglia and contributes to the induction and maintenance of the CS [52]. SP and CGRP are released from the peripheral endings of sensory neurons, which contribute to the development of neurogenic inflammation, while SP and CGRP are released from the central terminal of sensory neurons, which contribute to enhanced nociception and the buildup of CS [50]. Neuronal sensitization mediated by NGF/TrkA increases nociceptive signaling through the DH and supraspinal structures [42]. The overall effect is the condition of CS.

The release of NGF during cartilage degradation, bone remodeling, and synovial inflammation appears to play a pivotal role in the mechanical hyperalgesia that occurs in OA patients with pain symptoms. Results in models are illustrative: in one rat model, systemic administration of NGF caused mechanical and thermal hyperalgesia [33], while in rat models of OA, intra-articular injection of NGF produced a decrease in the hind paw mechanical withdrawal threshold in one [54] and contributed to spinal nociceptive sensitization in another [55]. Our previous study described a positive correlation between expression levels of NGF mRNA in the synovial membrane and scores for the central sensitization inventory (CSI) and pain in patients with HOA [41]. These findings support previous evidence that monoclonal antibodies against NGF reduce pain symptoms from OA [56-58]. However, evidence for a direct association between PS and CS in human OA and NGF levels in intra-articular tissues such as synovial membrane, synovial fluids, cartilage, etc. is lacking, and further study is required.
Clinical characteristics of sensitized pain in OA

Pain sensitization in people with OA has been assessed using a variety of measures. It is common to perform quantitative sensory testing (QST) as a method of assessment, utilizing standardized mechanical, thermal, or electrical test modalities to assess sensitivity to noxious or innocuous stimuli [64,66]. In a systematic review, PPT data were analyzed in comparison with healthy controls for people with OA. According to the study, pain sensitization was evident at affected and remote anatomical test sites for people with OA [66]. In addition, Lundblad et al. demonstrated that total knee arthroplasty (TKA) for KOA was not always followed by a complete resolution of pain symptoms [67]. Of note, the risk of persistent pain after TKA was increased in subjects with high pre-operative pain scores and low pre-operative local PPTs. In the study using the QST, the purpose was essential to assess the association between the level of the QST and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) post-operative pain after the surgery [68]. The high QST group had more severe WOMAC pain after the surgery at one year compared to the low QST group [68].

In recent years, CS was also assessed by the CSI in patients with OA [69]. This questionnaire, which was designed to evaluate the symptoms associated with CS, includes 25 self-reported items on somatic and emotional symptoms, each of which is scored between 0 and 100 points, with 0 and 100 being the best and worst scores, respectively. According to a 5-point Likert scale, each of the items was graded on a scale of 0 = never, 1 = rarely, 2 = sometimes, 3 = often, and 4 = always. There has been a significant impact on post-operative pain residuals as well as a decrease in satisfaction with CS in studies evaluated by CSI [70-72]. Our previous study suggested that the pre-operative CSI score was negatively correlated with pain and satisfaction scores at 12 months after surgery in patients undergoing total hip arthroplasty (THA) for HOA [70]. Further, a high pre-operative CSI score (>40) is reported to negatively impact post-operative residual pain and satisfaction, as well as the quality of life in patients who underwent TKA for KOA [71,72].

Several studies have described characteristic pain symptoms for detecting sensitized pain. One of these is expanded pain in KOA and HOA. Willett et al. described that expanded pain - assessed by digital pain drawings - was significantly associated with lower PPTs at the thenar eminence, vastus lateralis, and greater trochanter in patients with HOA [73]. Iluch et al. noted that in patients with KOA, the area of expanded pain was associated with lower PPT at the epicondyle and knee and higher CSI scores [74]. Pain at rest is another characteristic of sensitized pain. Satake et al. revealed that the degree of resting pain assessed with a visual analog scale (VAS) was associated with local PPT compared with walking pain in KOA patients [75]. We have reported that VAS resting pain positively correlated with CSI score in patients with HOA [76]. One study suggested that nocturnal pain in KOA is a characteristic symptom of sensitized pain. Sasaki et al. reported that in patients with non-CS, and found a positive correlation between CSI score and sleep quality determined with the Pittsburgh sleep quality index [77]. These clinical characteristics of sensitized pain are thought to be caused by pathologies of PS and CS.

Treatments for OA pain related to PS and CS

There are several pharmacologic therapies that have the potential to improve OA pain related to PS and CS.

Anti-Inflammatory Cytokine Drugs

Several studies indicated the efficacy and safety of anti-inflammatory cytokine drugs such as human TNF-α or IL-6 monoclonal antibodies for rheumatic diseases, such as RA [78,79]. The evidence on the effectiveness of these drugs for OA pain is limited. A meta-analysis suggested that etanercept and infliximab were superior to placebo for pain in KOA, and infliximab was superior to the other biologic agents (adalimumab, anakinra, canakinumab, etanercept, naproxen, and tocilizumab) in improving pain in the hands and knees of OA [80]. In contrast, several clinical trials have been reported that specifically for OA of the hand, none seem to have shown the efficacy of a monoclonal antibody against TNF-α and IL-6 [81-85]. However, there were no ongoing trials using anti-inflammatory cytokine drugs for OA pain on clinicaltrials.gov.

Tanezumab

Tanezumab is a monoclonal antibody against NGF, which reduces pain symptoms more effectively than other analgesics in moderate-to-severe KOA and HOA [57,84,85]. In a short-term study of KOA and HOA, tanezumab by intravenous administration produced a greater improvement in pain and function than NSAIDs and opioids [85]. A recent phase III randomized controlled trial demonstrated long-term efficacy on subcutaneous administration compared with non-steroidal anti-inflammatory drugs (NSAIDs) in patients with moderate or severe HOA or KOA [84]. However, test group patients were at increased risk of abnormal peripheral sensation and rapidly progressive joint damage compared to the control groups [57,84-86]. NGF inhibitors may effectively improve pain symptoms in OA patients, but the reason why blocking NGF leads to rapid OA progression warrants careful examination.

Duloxetine
Duloxetine, a potent and selective serotonin-norepinephrine reuptake inhibitor, has attracted attention as a potentially useful analgesic for sensitized pain in OA [87]. In RCTs, this agent, which facilitates descending inhibitory pain pathways in the CNS [88], reduced pain and improved function and QOL in patients with KOA and HOA [89-91]. In their 10-week double-blind RCT in patients with severe KOA, Frakes et al. revealed that the addition of duloxetine to oral NSAID therapy offered significant additional pain reduction than NSAIDs alone [92]. Interestingly, pre-operative administration of duloxetine also seems to improve residual pain in the early post-operative period after arthroplasty. Among patients with CS (CSI scores ≥40) and severe KOA, Koh et al. reported that patients receiving duloxetine from the day before surgery to six weeks after surgery had greater pain reduction in the initial 2- to 12-week post-operative period than control patients (no duloxetine) [93]. Future studies should focus on assessing the long-term safety of duloxetine.

Drugs in the ongoing clinical trial phase for OA pain related to PS and CS

There are several drugs with potential future applications for OA pain that are currently in clinical trials (phase II or phase III) (Table 1). This section includes some drugs that target the cannabinoid receptor, TRPV1, and bradykinin B2 receptor in the clinical trial phase registered on www.clinicaltrials.gov for treating OA.

<table>
<thead>
<tr>
<th>Target</th>
<th>Drug</th>
<th>Mechanism of action</th>
<th>Phase</th>
<th>NCT</th>
<th>Status</th>
<th>Sponsor/Collaborators</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cannabinoid receptors</td>
<td>Cannabidiol</td>
<td>Cannabinoid receptor agonists</td>
<td>II</td>
<td>NCT04992624</td>
<td>Recruiting</td>
<td>Richard Harris National Center for Complementary Health National Institution Drug Abuse University of Michigan</td>
</tr>
<tr>
<td>Cannabinoid receptors</td>
<td>Cannabidiol and Cannabinol</td>
<td>Cannabinoid receptor agonists</td>
<td>II</td>
<td>NCT04992962</td>
<td>Recruiting</td>
<td>Pure Green</td>
</tr>
<tr>
<td>Cannabinoid receptors</td>
<td>LY2920360</td>
<td></td>
<td></td>
<td>NCT01319690</td>
<td>Completed</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>TRPV1</td>
<td>RTX-GRT7039</td>
<td>TRPV1 agonist</td>
<td>II</td>
<td>NCT00346386</td>
<td>Not yet recruiting</td>
<td>Grünenthal GmbH</td>
</tr>
<tr>
<td>TRPV1</td>
<td>Resiveratxin</td>
<td>Resiveratxin</td>
<td>II</td>
<td>NCT04980702</td>
<td>Active, not recruiting</td>
<td>Sorrento Therapeutics, Inc.</td>
</tr>
<tr>
<td>TRPV1</td>
<td>Fasitibant</td>
<td>B2 receptor antagonist</td>
<td>II</td>
<td>NCT03303056</td>
<td>Completed</td>
<td>Menarini Group</td>
</tr>
<tr>
<td>TRPV1</td>
<td>Icatibant</td>
<td>B2 receptor antagonist</td>
<td>II</td>
<td>NCT01091116</td>
<td>Completed</td>
<td>Menarini Group</td>
</tr>
<tr>
<td>TRPV1</td>
<td>NCT02205814</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**TABLE 1: Drugs in the ongoing clinical trials for osteoarthritis pain related to peripheral and central sensitization**

Drugs targeting the cannabinoid receptors

The cannabinoid receptors CB1 and CB2 belong to the family of G-protein-coupled receptors and bind exogenous ligands derived from Cannabis sativa as well as endogenous arachidonic-derived ligands. CB2 receptors are primarily expressed in cells of the immune system, including macrophages, and regulate the pro-inflammatory response in various settings [94]. CB2-selective agonists display anti-nociceptive activity in well-validated models of persistent inflammatory pain and neuropathic pain [95]. However, placebo-controlled RCTs indicated that LY2820360, the CB2-selective agonist, lacked both toxicity and efficacy for suppressing KOA pain (clinicaltrials.gov identifier: NCT01319929). Two RCTs in phase II with cannabidiol and cannabinol are currently ongoing for KOA pain (clinicaltrials.gov identifiers: NCT04992624, NCT04992962).

Drugs targeting the TRPV1

The TRP superfamily of ion channels comprises proteins with six transmembrane domains and cytoplasmic N- and C-termini. TRP proteins assemble as homo- or heterotetramers to form cation-permeable ion channels. Twenty-eight TRP channels have been discovered in mammals based on their sequence homology,
are classified into six subfamilies [96]. The vanilloid receptor TRPV1 is a homo-tetrameric, non-selective cation channel abundantly expressed in the nociceptors [97]. TRPV1 is considered a validated target for OA pain treatment because its agonists, such as capsaicin, cause desensitization of TRPV1 channels that reduce pain levels in preclinical species, and its antagonists also reduce pain levels in rodent models of OA [98,99].

A recent potential advance in OA pain management is the development of an intra-articular capsaicin formulation, thereby overcoming the likely limited permeability of topical capsaicin into the knee joint [100]. A capsaicin injection into the knee joint was well tolerated and provided dose-dependent improvement in knee OA pain with walking [100]. Currently, two intra-articular injection agents, TRPV1 agonists, are in clinical trials of phases II and III for patients with KOA (clinicaltrials.gov identifiers: RTX-GRT7039, NCT05248386, NCT05449132, and NCT05377489; Resiniferatoxin, NCT04885972). Further elucidation of the analgesic efficacy and safety of TRPV1 agonists should lead to effective non-opioid analgesic options.

**Drugs targeting the bradykinin B2 receptor**

Bradykinin is known to have potent pro-inflammatory effects and is one of the most potent endogenous algogenic peptides. This peptide is formed in plasma and inflamed tissues and, by activating the G-protein-coupled receptor, B2 receptor, promotes the activation of nociceptive neurons [44]. Further, elevated bradykinin levels have been demonstrated in the synovial fluid of patients with OA [101]. Thus, bradykinin is an endogenous pro-inflammatory molecule that is associated with the pathophysiology of OA, and B2 receptor antagonists are believed to be considered as a potential symptomatic therapy for this disease. Icatibant and Fasitibant, which are B2 receptor antagonists, have been carried out in phase II of the clinical trials (clinicaltrials.gov identifiers: Icatibant, NCT00303056; Fasitibant, NCT01091116; and NCT0205814). However, no direct evidence of efficacy seems to be indicated. There is a need for further clinical trials to better explain the mechanisms of action and the efficacy and tolerability of the B2 receptor antagonists in OA.

**Conclusions**

In this review, we reported findings on the pathophysiology of PS and CS in OA pain and the clinical features and treatment of sensitized pain. Considering the pathophysiology of sensitized pain in OA and the complex clinical features associated with it, accelerating the development of new therapies is important.

Several drugs have been tested in clinical trials to improve sensitized pain caused by OA. Among them, duloxetine appears to be highly efficacious and safe for sensitized pain in OA. Additionally, some drugs targeting cannabinoid receptors, TRPV1 receptors, and bradykinin B2 receptors are currently being tested in clinical trials for the treatment of OA pain caused by PS or CS. These drug targets have the potential to provide better results in alleviating OA pain since they are involved in the pathogenesis of PS and CS. Treatments for sensitized pain in OA are still in their infancy, however, and additional basic and clinical investigations are needed.

**Additional Information**

**Disclosures**

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

7. Thakur M, Dawes JM, McMahon SB: Genomics of pain in osteoarthritis. Osteoarthritis Cartilage. 2015, 23:1574-82. 10.1016/j.joca.2015.06.010
8. Schaible HG, Ebersberger A, Natura G: Update on peripheral mechanisms of pain: beyond prostaglandins

through Rasch analysis in patients with knee osteoarthritis.


Schnitzius T, Marks JA: A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthritis Cartilage. 2015, 23 Suppl 1:S8-17. 10.1016/j.joca.2014.10.005


Samanta A, Hughes TE, Moiseenkova-Bell VV: Transient receptor potential (TRP) channels. Subcell